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Background: Vascular Endothelial Growth Factor (VEGF) is regulated by a number of different factors, but the
mechanism(s) behind androgen-mediated regulation of VEGF in prostate cancer are poorly understood.
Results: Three novel androgen receptor (AR) binding sites were discovered in the VEGF promoter and in vivo
binding of AR to these sites was demonstrated by chromatin immunoprecipitation. Mutation of these sites
attenuated activation of the VEGF promoter by the androgen analog, R1881 in prostate cancer cells. The
transcription factors AR and Sp1 were shown to form a nuclear complex and both bound the VEGF core
promoter in chromatin of hormone treated CWR22Rv1 prostate cancer cells. The importance of the Sp1
binding site in hormone mediated activation of VEGF expression was demonstrated by site directed
mutagenesis. Mutation of a critical Sp1 binding site (Sp1.4) in the VEGF core promoter region prevented
activation by androgen. Similarly, suppression of Sp1 binding by Mithramycin A treatment significantly
reduced VEGF expression.
Conclusions: Our mechanistic study of androgen mediated induction of VEGF expression in prostate cancer
cells revealed for the first time that this induction is mediated through the core promoter region and is
dependent upon a critical Sp1 binding site. The importance of Sp1 binding suggests that therapy targeting
the AR-Sp1 complex may dampen VEGF induced angiogenesis and, thereby, block prostate cancer
progression, helping to maintain the indolent form of prostate cancer.Background
In the United States, prostate cancer is the most fre-
quently diagnosed cancer in men with more than 200,000
new cases each year and the second most deadly, killing
roughly 30,000 men annually [1]. Prostate cancer growth
is dependent upon an adequate blood supply, which is
controlled by Vascular Endothelial Growth Factor (VEGF),
a regulator of tumor angiogenesis. Several factors are
known to modulate VEGF expression including growth
factors, cytokines, and hypoxia. Previous studies have also
shown that androgen increases VEGF levels [2-5], but the
mechanism(s) involved are unknown.
The VEGF promoter lacks a TATA box, is GC rich,
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distribution, and reproduction in any mediumas AP-2, HIF-1, Egr1, and WT1 [6-10]. Previously we
have reported the identification of functional WT1 bind-
ing sites within the proximal VEGF promoter [7,11], and
others have reported interaction of WT1 and HIF1-α in
the regulation of VEGF [8]. Additionally, Sp1/Sp3 bind-
ing sites located in the core promoter are known to play
a role in transcriptional regulation of VEGF in a variety
of cell lines including NIH3T3 cells [12], ZR-75 breast
cancer cells [13], Y79 retinoblastoma cells [14], NCI-
H322 bronchioloalveolar cells [15], and PANC-1 pancre-
atic cells [16]. Members of the Sp family have a con-
served C-terminal DNA binding domain, so they can
potentially bind the same sequence of DNA and indeed
Sp1, 3, and 4 bind preferentially bind at GC-boxes [17].
However, binding at different sites within a promoter re-
gion may also confer different functional responses for
Sp1 and Sp3 [18]. A cluster of Sp1/3 sites in the prox-
imal promoter mediates regulation of VEGF by TNF-αtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for IL-1β induction of VEGF transcription in cardiac
myocytes [20] and for TGF-β1 stimulation of VEGF
transcription in cholangiocellular carcinoma cells [21].
In Panc-1 pancreatic cells, the regulation of VEGF by
Sp1 has been extensively documented [16,22] and both
constitutive Sp1 activity and a 109 bp core promoter re-
gion containing Sp1 sites are essential for VEGF expres-
sion [16]. Overall, the transcriptional regulation of VEGF
is cell specific involving different stimuli and factors, but
Sp1 plays a prominent role in many cell types.
Since estrogen mediated regulation of VEGF expres-
sion in ZR-75 breast cancer cells was shown to require
Sp1 sites in the core VEGF promoter [13], we asked
whether androgen might behave similarly in prostate
cancer cells. Previous studies have demonstrated that
VEGF mRNA levels are elevated by androgen treatment
of both human fetal prostatic fibroblasts and LNCaP
prostate cancer cells [2,4,5]. Also, VEGF protein levels
are increased after treatment with hormone [3] and flu-
tamide, an anti-androgen, has been shown to block this
up-regulation [23]. However, the hormone responsive re-
gion of the VEGF promoter was never identified in these
earlier studies, nor was the mechanism of androgen in-
duction of VEGF promoter activity and VEGF mRNA
expression determined.
This report characterizing the hormone responsive
regions and binding sites within the VEGF promoter is a
continuation of earlier studies analyzing conserved puta-
tive binding sites in promoters of genes expressed in
prostate cancer [11] that identified potentially important
non-classical AR binding sites adjacent to other zinc fin-
ger transcription factor binding sites in the promoter of
VEGF and other genes [24]. Here we identified and char-
acterized the hormone responsive regions of the VEGF
promoter, including a required Sp1 binding site within
the core promoter.
Results
Androgen induces VEGF expression and AR binding to
chromatin of prostate cancer cells
To determine whether VEGF expression was activated by
androgen in prostate cancer cells, CWR22Rv1 (22Rv1) cells
were treated with the androgen analog R1881. Cells were
serum starved overnight and then treated with 5nM R1881
for 48 hours. Figure 1A shows a two-fold increase in VEGF
mRNA expression in response to androgen, as measured
by quantitative real-time PCR (qRT-PCR). Similar effects
were observed in LNCaP cells treated with 1nM R1881
(Additional file 1) and 5nM R1881 (Figure 1B). To confirm
that androgen induction of VEGF required hormone-AR
interaction, the effect of anti-androgen treatment was then
examined using bicalutamide (casodex). LNCaP cells were
pre-treated with 0 μM or 10μM casodex for 2 hrs and thentreated with 5nM R1881 for 24 hours. Casodex treatment
significantly reduced the hormone activation of VEGF
mRNA indicating that classical signaling requiring AR-
androgen interaction was occurring (Figure 1B). Inhibition
of hormone induced VEGF expression by casodex was
confirmed in 22Rv1 cells (data not shown). Given that hor-
mone enhanced VEGF mRNA levels, VEGF protein ex-
pression was also examined in LNCaP cells treated with
androgen. As shown in Figure 1C, VEGF protein expres-
sion increased after 1 hour of treatment with 1nM R1881
and maximal expression was seen after 48 hours, which
was similar to mRNA expression. Blockade of classical an-
drogen signaling by casodex treatment also decreased hor-
mone mediated up-regulation of cytoplasmic VEGF
protein levels by more than 70%. (Figure 1D). To deter-
mine whether casodex also blocked a hormone mediated
increase in nuclear AR protein levels, nuclear extracts were
isolated and western blot analysis was performed. AR pro-
tein levels in nuclear lysates prepared from LNCaP cells
treated with 0nM or 1nM R1881 and with 0μM or 10μM
casodex were examined, and casodex was shown to signifi-
cantly reduce AR protein levels (data not shown).
Having confirmed classical hormone mediated VEGF
up-regulation, potential ARE binding sites within the
VEGF promoter were then identified using MatInspector
software, as previously described [24]. Transcription factor
binding site prediction analysis of the VEGF promoter se-
quence revealed numerous transcription factor binding
sites including Sp1, WT1, and Egr1 sites as well as three
potential ARE binding sites within 2kb of the transcription
start site in the VEGF promoter. Since these ARE sites
(Figure 2A) were non-classical monomeric sites, it was
important that they be tested for functional binding using
chromatin immunoprecipitation (ChIP). LNCaP cells were
serum starved overnight and then treated with 0nM or
5nM R1881 for 24 hours. As shown in Figures 2B-D,
chromatin of hormone treated LNCaP cells was immuno-
precipitated with anti-AR antibody and amplified by three
primer sets flanking the regions containing the three puta-
tive ARE binding sites (Figure 2A). Hormone treatment
enhanced AR binding, as indicated by both standard end-
point PCR (Figures 2B-D) and SYBR Green quantitative
qRT-PCR (Figure 2E). Results were quantified as a per-
centage of input chromatin and showed approximately 2-
fold increase of chromatin immunoprecipitated by AR
antibody in cells treated with 5nM R1881 compared to
that of untreated cells (Figure 2E). These results suggested
that all three binding sites were functional and might be
important in the hormone regulation of VEGF.
Three non-classical ARE sites contribute to the hormone
response of the VEGF promoter
To determine whether AR binding regions identified by
ChIP were transcriptionally activated by hormone, a
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Figure 1 Androgen regulates VEGF expression in LNCaP and 22Rv1 prostate cancer cells. (A) 22Rv1 cells were serum starved overnight
then treated with 5nM R1881 or DMSO as a vehicle control (0nM R1881). VEGF mRNA expression was measured by qRT-PCR and normalized by
β-actin levels as described in text. (B) VEGF mRNA expression in LNCaP cells was measured by qRT-PCR and normalized by 18S levels, as
described in text. Cells were serum starved as described in A. For inhibition of androgen activity, cells were pre-treated with 10μM casodex for 2
hrs and then induced with 5nM R1881 for 24 hrs. Values represent fold change relative to DMSO treatment. A Student’s t-test was performed and
significance was determined * (p < 0.05), ** (p < 0.01). (C) VEGF protein expression in LNCaP cells treated with 1nM R1881 for 0–48 hours. Protein
expression was measured by western blotting as described in text, and β-actin levels were used as loading controls. (D) Cytoplasmic VEGF
protein expression was measured by western blot of LNCaP cells treated as per (B). Image J analysis was performed and VEGF levels were
normalized to β-actin levels. Shown are relative fold-changes in VEGF protein levels, normalized to β-actin and relative to untreated cells.
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http://www.molecular-cancer.com/content/12/1/7series of VEGF promoter deletion constructs were
obtained [16] ranging in length from 88 bp (V88) to 2274
bp (V2274). Figure 3A shows the location of predicted
Sp1, WT1, Egr1, and AR transcription factor binding sites
within the 2kb promoter region. These constructs were
tested in luciferase assays to determine where within the
VEGF promoter the hormone responsive element(s) were
located. LNCaP and 22Rv1 cells were transfected with a
411 bp (V411) construct containing only the ARE I site
and treated with either increasing doses of R1881 (0.05 to
5nM) (Figure 3B) or 5nM R1881 with 10μM casodex
(Figure 3C and D). After 48 hours, cells were lysed and
luciferase assays were performed. 22Rv1 cells were shown
to be highly sensitive to androgen as even 0.5nM R1881
increased VEGF promoter activity more than 2 fold
(Figure 3B). Similarly, in 22Rv1 cells an almost 2 fold in-
crease in VEGF promoter activity was seen in cells treated
with 5nM R1881 and casodex blocked this activation
(Figure 3C). Additionally, LNCaP cells treated with 5nM
R1881 showed a greater than a 2.5 fold increase in VEGF
promoter activity when compared to cells treated with
the DMSO vehicle control (Figure 3D). Confirming therequirement for AR-hormone interaction, casodex treat-
ment inhibited this androgen response in LNCaP cells
(Figure 3D). Since ARE II and III lie outside of the V411
region, a larger promoter construct (V2274) was examined
in 22Rv1 cells to determine whether hormone activation
of VEGF was greater in the 2kb reporter construct con-
taining all three ARE binding sites. As shown in Figure 3E,
hormone activation of V2274 was increased (3.5 fold) in
this larger construct, greater than the response shown in
the smaller 411 bp reporter construct containing only
ARE I. This suggested that all three ARE sites may con-
tribute to androgen activation of the VEGF promoter, al-
though not synergistically.
To determine which ARE sites might be required for an-
drogen mediated up-regulation of the VEGF promoter, all
three ARE binding sites were mutated and mutations were
confirmed by sequence analysis. Mutations were initially
made in the larger V2274 reporter construct which con-
tains all three ARE binding sites (Figure 4A). Site-directed
mutagenesis was performed using PCR primers designed
to contain base substitutions in either the ARE II or ARE
III sites in the V2274 construct (Figure 4B). The effect of
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Figure 2 Hormone treatment enhances AR protein binding to the VEGF promoter in chromatin of LNCaP cells. (A) Schematic diagram of
the VEGF promoter showing the location of predicted ARE binding sites and primers used to amplify the specific regions of the promoter. (B)
ChIP assays were performed with primers specific for the ARE I region of the VEGF promoter using chromatin prepared from LNCaP cells treated
for 24 hours with either 0nM R1881 or 5nM R1881, following overnight serum starvation. Standard endpoint PCR was performed as described in
text. Lane 1 shows amplification of input chromatin that was not immunoprecipitated with antibody, lane 2 chromatin immunoprecipitated with
anti-pol II antibody (Upstate), lanes 3 and 4 chromatin from cells treated with 0nM or 5nM R1881 and immunoprecipitated with anti-AR (Santa
Cruz) antibody and lane 6 is the negative control precipitated with IgG (Upstate). Chromatin amplified in lane 3 was obtained from cells treated
with vehicle (DMSO) only. (C) PCR was performed using chromatin as described in (B) and primers specific for the ARE II region (shown in A).
Lane 1 is the no DNA control, lane 2 is input diluted 1:10, lane 3 is undiluted input, lanes 4 and 5 chromatin from cells treated with 0nM or 5nM
R1881 and immunoprecipitated with anti-AR antibody, and lane 6 is the IgG negative control precipitation. Chromatin amplified in lane 4 was
obtained from cells treated with vehicle (DMSO) only. (D) PCR was performed using chromatin as described in (B) and primers specific for the
ARE III region. Lanes are the same as in (C). (E) Quantification of immunoprecipitation was performed by SYBR Green qRT-PCR using primers
described in (A). Chromatin was immunoprecipitated with anti-AR antibody from LNCaP cells treated with 0nM or 5nM R1881 as described
above. Average Ct values of immunoprecipitated chromatin were normalized to input and normalized values from 5 nM R1881 treated cells are
shown relative to untreated cells (0nM R1881).
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http://www.molecular-cancer.com/content/12/1/7eliminating ARE binding at the ARE II or III sites was
tested by luciferase reporter assays performed in 22Rv1
cells. Transfections of 22Rv1 cells were followed by hor-
mone treatment and the wild type V2274 promoter con-
struct was up-regulated approximately 3 fold by 5nM
R1881 and this response was attenuated in the mutant
constructs to approximately 2 fold activation (Figures 4C
and D). Double mutation of both ARE II and III sites in
V2274 showed similar retention of residual hormone acti-
vation when compared to wild type (data not shown). To
determine the contribution of ARE I, the V411 reporter
construct containing only the ARE I site was mutated as
described (Figure 4B) and the effect was tested by lucifer-
ase reporter assays performed in both 22Rv1 and LNCaP
cells. Figure 4E shows that in 22Rv1 cells, the wild type
V411 promoter was up-regulated more than 3 fold by5nM R1881 and this response was attenuated in the mutant
ARE I V411 construct to less than 2 fold activation. A simi-
lar effect was also seen in LNCaP cells (Figure 4F), although
in this case the residual hormone response of the mutant
ARE I -V411 construct was not significant. Overall the hor-
mone response of the mutant ARE I promoter was reduced
approximately 2-fold in both LNCaP and 22Rv1 cells.
Since single or double mutation of the three ARE sites
did not completely eliminate hormone response, we rea-
soned that one possibility was that all three sites were re-
dundant. However, mutation of two of three ARE sites did
not reduce hormone activation to any greater extent than
one site alone (data not shown). Another possibility was
that other TFs were involved in the hormone response.
Thus, we examined the involvement of Sp1, another ZFTF
known to regulate VEGF transcription in other systems.
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Figure 3 Hormone activates the VEGF promoter in two different cell lines, LNCaP and 22Rv1. (A) Schematic diagram of the VEGF promoter
showing locations of predicted ARE binding sites (grey boxes) in relation to 5’ termini of luciferase reporter constructs V411 and V2274 [16]. (B)
22Rv1 cells were transfected with the 411 bp VEGF promoter construct (V411) in the presence or absence of different concentrations of R1881 (0,
0.05nM, 0.5nM, and 5nM) for 48hrs. Luciferase assays of cell lysates were performed and fold activation was determined as described in text. (C)
22Rv1 cells were transfected with V411 and treated with 0nM R1881, or 5nM R1881 with 0μM casodex, or 5nM R1881 with 10μM casodex for 48
hrs. (D) LNCaP cells were transfected and treated as per (C). (E) 22Rv1 cells were transfected with the 2274 bp VEGF promoter construct (V2274)
and treated as per (C). Luciferase activity is shown relative to average normalized luciferase activity in the absence of hormone. Experiments were
repeated three times in triplicate. Significance was determined by Student’s t-test (*p<0.05, ** p<0.01, ***p<0.001).
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http://www.molecular-cancer.com/content/12/1/7Sp1 binding site in the VEGF core promoter is required
for hormone responsiveness
Given that potential Sp1 binding sites were also identified
in the VEGF promoter region and Sp1 was observed to
bind the VEGF promoter in chromatin of LNCaP cells
[11], we asked whether Sp1 binding might contribute to
androgen activation of the VEGF promoter. Although the
V88 core promoter region is a very G-rich region, contain-
ing multiple potential Sp1 binding sites (Figure 5A), it was
not expected to respond to hormone induction, as it does
not contain any ARE binding sites. Initially, to test the hor-
mone response of the core promoter, 22Rv1 cells were co-
transfected with the V88 reporter construct followed by
treatment with R1881. Luciferase assays were performed
and surprisingly androgen activated this VEGF core pro-
moter region almost 2-fold (Figure 5B). To confirm this
hormone activation was mediated by AR/androgen inter-
action, V88 transfected 22Rv1 cells were treated with caso-
dex. Figure 5C shows that casodex treatment completely
blocked the androgen activation of V88, implicating clas-
sical androgen signaling at the GC-rich core promoter.
Since the core promoter contains multiple Sp1 binding
sites and Mithramycin A is an inhibitor of transcriptionfactor binding to GC rich promoters, we treated 22Rv1
cells with 0.1μM of Mithramycin A for 24 hours to block
Sp mediated activation of the VEGF promoter. RNA was
isolated and qRT-PCR was performed to determine the ef-
fect on VEGF mRNA levels. Figure 6A shows that, as
expected, Mithramycin A treatment suppressed VEGF
expression as well as Sp1, itself. VEGF mRNA levels were
repressed more than 5 fold, and Sp1 more than 2.5 fold, in
the presence of Mithramycin A. To confirm the necessity
of Sp1 binding, site-directed mutagenesis was used to mu-
tate three potential Sp1 binding sites within the core pro-
moter. Primers were designed incorporating mutations
for both the Sp1.2 and Sp1.3 binding sites as shown
(Figure 6B). Hormone treatment significantly activated the
core promoter containing mutant Sp1.2/.3 binding sites
(2.5 fold) as demonstrated by luciferase assays of R1881
treated 22Rv1 cells (Figure 6B). This suggested that these
two potential Sp1 binding sites were not essential for hor-
mone response, so another Sp1 binding site (Sp1.4) closer
to the transcriptional start site was examined. Mutation of
this site completely suppressed activation by R1881
(Figure 6C). That is, wild-type core promoter was acti-
vated by hormone treatment 3 fold, whereas the mSp1.4
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Figure 4 Mutation of ARE sites attenuate hormone activation of the VEGF promoter. (A) Schematic diagram of a 2kb region of the VEGF
promoter showing the ARE I-III binding sites. Thick X’s indicate sites that were mutated. (B) Shown are the wild type (WT) and mutant (MUT)
sequences of the ARE I, ARE II, and ARE III binding sites. Site-directed mutagenesis was performed as described in text, using primers containing
these mutated bases. (C) Wild type V2274 and mutant (mARE II) luciferase reporters were transfected into 22Rv1 cells treated with 0nM or 5nM
R1881 for 48 hrs. Luciferase assays were performed as previously described. (D) Mutant (mARE III) and wild type V2274 were transfected into
22Rv1 cells as in (C). (E) Wild type and mutant V411 constructs were transfected into 22Rv1 cells as in C. (F) The mutant V411 construct was also
transfected into LNCaP cells and treated as in C. Luciferase activity is shown relative to average normalized luciferase activity in the absence of
hormone. Experiments were repeated three times in triplicate. Significance was determined by Student’s t-test (**p<0.01).
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http://www.molecular-cancer.com/content/12/1/7mutant core promoter was not significantly activated (1.3
fold increase). This reduction of hormone response sug-
gested that the Sp1.4 site was required for a full-strength
response of the core promoter to R1881.
To address the possibility that mutation of the Sp1.4
site resulted in a loss of both basal VEGF expression and
the induced hormone mediated response we asked
whether the mutation altered basal activity. If Sp1 bind-
ing at the Sp1.4 site was required for basal transcription,
then we would predict both hormone and basal response
would be reduced by the mutation. Therefore we com-
pared the basal expression levels of the mutant mSp1.4
promoter construct to the empty vector and found that
there was still significant basal transcription occurring
(Additional file 2). This data suggests that while the
Sp1.4 binding site was essential for hormone response, it
was not required for basal activity. Since mutation of
Sp1.4 in the V88 construct eliminated androgen induc-
tion of the core promoter, it was important that this
binding site also be mutated in the V2274 promoter con-
struct to confirm that the Sp1.4 binding site regulated
hormone activation of the full length promoter region,
which contains all three ARE binding sites. This wasindeed the case, as mutating Sp1.4 within the V2274 con-
struct decreased induction by R1881 (Figure 6D). This was
consistent with Figure 6A, which demonstrated transcrip-
tional suppression of the endogenous VEGF promoter by
Mithramycin A, an inhibitor of Sp1 binding. Overall the
data demonstrated the critical role of the Sp1.4 binding site
for hormone mediated activation of VEGF expression.
AR and Sp1 interact in the nucleus and both bind the
VEGF core promoter in chromatin
In addition to these reporter assays showing that the
Sp1.4 binding site was required for androgen mediated
up-regulation of the VEGF promoter, prior electrophor-
etic mobility shift assays (EMSA) of the VEGF core pro-
moter had also shown that an oligonucleotide sequence
containing the Sp1.4 site bound purified Sp1 proteins
in vitro [7]. Here, we determined whether Sp1 would
bind the VEGF promoter in vivo. ChIP analysis was per-
formed to determine if both Sp1 and AR bound to the
GC- rich core VEGF promoter in chromatin of hormone
treated 22Rv1 cells (Figure 7A). Sp1 and AR immuno-
precipitated chromatin was quantified by qRT-PCR and
results clearly show that both Sp1 and AR bound to this
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Figure 5 Hormone activates the VEGF minimal core promoter region lacking ARE sites. (A) Schematic diagram of an 88bp region of the
VEGF core promoter showing four predicted Sp1 (black box) and Egr1 (white box) binding sites. (B) 22Rv1 cells were transfected with V88
followed by treatment with 0nM or 5nM R1881 as described above. Luciferase assays were performed as previously described. (C) 22Rv1 cells
were transfected as in (B) except pre-treated with 0μM or 10μM casodex for 2 hours. Luciferase activity is shown relative to average normalized
luciferase activity in the absence of hormone. Experiments were repeated three times in triplicate. Significance was determined by Student’s t-test
(*p<0.05, ** p<0.01).
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http://www.molecular-cancer.com/content/12/1/7GC-rich region. In cells treated with 5nM R1881, 10-
fold more chromatin was immunoprecipitated by Sp1
antibodies than in untreated cells. Similarly, hormone
treatment increased AR binding to this region by more
than 5 fold, despite the absence of ARE sites. These
results indicate that both AR and Sp1 were bound to the
core VEGF promoter region and suggested the possibil-
ity that they might form a complex tethering AR to Sp1
binding sites within the core promoter.
Although AR and Sp1 have previously been demon-
strated to interact in LNCaP cells [25], it was unclear
whether these two zinc finger transcription factors would
form a complex in 22Rv1 cells. Nuclear lysates from 22Rv1
cells were immunoprecipitated using AR and Sp1 anti-
bodies as well as a negative control IgG. Using Western
blot analysis, the immunoprecipitated proteins were then
probed with AR antibody. In the absence of hormone, little
AR protein was precipitated by AR antibody and none by
Sp1 antibody (Figure 7B, upper panel). In contrast, in the
presence of 5nM R1881, AR protein was immunoprecipi-
tated by both Sp1 and AR antibodies (Figure 7B, lower
panel). This co-immunoprecipitation was hormone spe-
cific, occurring only in cells that were treated with 5nM
R1881, indicating that Sp1/AR complex formation was an
androgen dependent interaction. This hormone dependent
complex formation is consistent with hormone mediated
binding and activation of the VEGF core promoter.Discussion
We and others have previously demonstrated that andro-
gens up-regulate VEGF expression [3,4,7,23], however,
mechanisms involved were not elucidated. Therefore, a
molecular understanding of how androgens regulate VEGF
in prostate cancer cells was sought. In this study, we firmly
established VEGF as a hormone responsive gene and
demonstrated that the Sp1.4 binding site located 50 bp
downstream of the transcription start site of VEGF was ne-
cessary for androgen activation of the VEGF core pro-
moter, a region lacking any potential ARE binding sites, yet
responsive to hormone treatment. Consistent with this
finding was the observation that Mithramycin A, which
inhibits Sp1 binding to GC rich promoter regions, signifi-
cantly decreased VEGF mRNA levels. Sp1 mediated hor-
mone activation of the VEGF core promoter likely involves
both DNA binding and AR protein interaction, as demon-
strated by ChIP and co-immunoprecipitation assays. These
results support a tethering model for hormone activation
of the VEGF core promoter, i.e., that ligand-bound AR is
recruited and then held in place by chromatin-bound Sp1
at the core promoter.
In delineating the hormone responsive regions of the
VEGF promoter, we initially focused on three potential
ARE sites and demonstrated DNA binding by ChIP and
transcriptional activation by R1881. However, mutations
of the three functional ARE half-sites merely attenuated,
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Androgens are known to regulate a multitude of genes,
with the most well studied androgen regulated gene being
PSA. There are three known dimeric ARE binding sites in
the regulatory region of PSA [26] and, similar to the VEGF
promoter, all three sites are involved in androgen regula-
tion. Although mutation of the two AREs in the proximal
promoter of PSA significantly decreased activation by
R1881, mutation of the ARE in the distal enhancer located
4kb upstream of the transcription start site completely
blocked androgen activation of PSA. In contrast to PSA,
the ARE sites in the VEGF promoter are monomeric sites,
not canonical dimeric ARE sequence, and are located
within 2 kb of the start site. One possibility is that binding
at these non-classical sites in the VEGF promoter may notbe as strong as that in the PSA promoter, but interaction
with other TFs might enhance or stabilize binding of AR,
increasing VEGF expression.
Since the VEGF promoter region is highly GC-rich we
investigated the role of other zinc finger transcription fac-
tors known to bind GC-rich promoter regions, such as
Sp1. Sp1/Sp3 binding sites in the core promoter region
are known to control VEGF transcriptional regulation in a
number of different cell lines. Sp1 mediates regulation of
VEGF in the presence of specific stimuli, such as stress
[27], estrogen [13], retinoic acid [14], TGF-β1 [21], and
PDGF [12] depending on the cell type. Androgens have
been known to act in concert with other zinc finger tran-
scription factors such as GATA [28] and Sp1 [25,29]
to regulate androgen responsive genes such as PSA, p21,
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for 48 hours prior to harvest, as described in Figure 2. Chromatin was immunoprecipitated with AR (Santa Cruz) or Sp1 (Upstate) antibodies, or
IgG (Upstate), then quantified by SYBR-Green qRT-PCR using primers specific for the VEGF core promoter region (as described in text). Values
shown are fold enrichment of Ab specific immunoprecipitations compared to IgG controls. (B) The interaction of AR and Sp1 in hormone treated
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http://www.molecular-cancer.com/content/12/1/7and NRIP. Previously, Sp1 sites have been shown to be
involved in androgen induction of both the p21 gene and
the NRIP (nuclear receptor interaction protein) gene and
co-IP demonstrated that AR interacts with Sp1 to regulate
their expression [25,29]. Similarly we have demonstrated
that Sp1 plays a role in the androgen responsiveness of
VEGF by forming a complex with AR and binding to the
VEGF promoter. While there are four Sp1 binding sites in
the core promoter region, mutation of a single binding
site, Sp1.4, eliminated androgen induction of this region
of VEGF. The VEGF promoter is similar to the NRIP pro-
moter, in that both are TATA-less GC rich promoters that
are induced by androgen in prostate cancer cells [29]. The
NRIP promoter also contains three Sp1 sites and two hor-
mone responsive elements (ARE and GRE). Similar to our
findings in the VEGF promoter, mutation of these ARE/
GRE sites did not eliminate hormone response; and Sp1
and AR were shown to cooperatively interact by several
methods, including sequential chromatin immunoprecipi-
tation and co-IP. In both these promoters, the association
of AR with Sp1 appeared to cooperatively regulate pro-
moter activity.
The mechanism of androgen mediated regulation of
VEGF identified by this study is analogous to estrogen
mediated regulation of VEGF in breast cancer cells [13].
We show here that androgen up-regulates the VEGF
core promoter, a region lacking ARE binding sites, but
containing four binding sites in which Sp1 or Sp3 can
bind. In ZR-75 breast cancer cells, estrogen regulation of
VEGF expression is thought to act through ER- α/Sp1
and ER- α/Sp3 interactions with GC-rich motifs [13].
These authors showed that treatment with estradiolincreased VEGF mRNA levels greater than fourfold.
Additionally, the GC-rich region of the VEGF core pro-
moter (−66 to −47) was required for E2 activation of
VEGF, despite a lack of classical ER binding sites. Both
Sp1 and Sp3 were demonstrated to bind the VEGF pro-
moter in vitro by EMSA and in vivo by ChIP, further
supporting their functional relevance in E2-mediated
regulation of VEGF. While these non-classical mechan-
isms of hormone mediated VEGF regulation operate
under normoxic conditions, under hypoxic conditions
HIF-1α is known to regulate VEGF expression. Andro-
gen regulation of VEGF by HIF-1α is thought to occur
indirectly through an autocrine loop involving EGF/
phosphatidylinositol 30-kinase/protein kinase B, which
activates HIF-1α and HIF-1α regulated expression of
VEGF under hypoxic conditions [23].
Conclusions
Androgen mediated regulation of VEGF expression
required a specific Sp1/3 binding site in the GC-rich
VEGF core promoter. Although ARE sites within the
VEGF promoter bound AR and their mutation dam-
pened VEGF expression, mutation of a key Sp1 binding
site in the core promoter of VEGF blocked promoter ac-
tivation by hormone. Our findings with androgen reflect
those of others examining regulation of VEGF by other
hormones [13-15]; overall these studies demonstrate the
complexity of hormone activation of VEGF and the im-
portance of protein-protein interactions. Regulation of
VEGF by zinc finger transcription factors, such as Sp1,
and the importance of their interactions with AR, sug-
gests that they may play a positive role in promoting
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http://www.molecular-cancer.com/content/12/1/7angiogenesis and prostate cancer progression. Thus, ele-
vated expression of these zinc finger transcription factors
may indicate a worse prognosis. Therapy disrupting AR-
Sp1 complexes and thereby suppressing VEGF would be
expected to limit angiogenesis and maintain the indolent
form of prostate cancer.
Methods
Cell culture and hormone treatment
LNCaP (ATCC CRL-1740) and CWR22Rv1 (ATCC
CRL-2505) prostate cancer cells were cultured in RPMI
media. All cells were grown in media supplemented with
10% FCS and 100ug/ml penicillin/streptomycin in a 37°C
incubator with 5% CO2. For hormone treatment, cells
were grown to 60-80% confluency and then serum starved
overnight in either serum-free media or media supple-
mented with 5% charcoal-dextran stripped FBS RPMI.
The synthetic androgen methyltrienolone (R1881) (Perkin
Elmer, Boston, MA) was then added to the charcoal-
dextran stripped FBS RPMI media and cells were treated
with 5nM R1881 for 24 hours unless otherwise noted in
figure legends. For inhibition of AR, 10μM bicalutamide/
casodex (LKT Labs, St. Paul, MN) was added 2 hours
prior to treatment with R1881.
Chromatin immunoprecipitation
Two million cells were treated with formaldehyde to
crosslink proteins to DNA and lysed as per manufacturer’s
recommendations using Millipore EZ ChIP Assay (Upstate
Biotechnology Inc., Billerica, MA). Chromatin was
sheared by sonication (Biosonik III, Bronwill Scientific,
Rochester, NY) to fragments of 200–1,000 bp in length.
The supernatant was pre-cleared by incubation with
Protein G Agarose and incubated overnight at 4°C with
either anti- AR (Santa Cruz), Sp1 (Santa Cruz) and control
polymerase II antibodies or non-immune IgG (Upstate
Biotechnology Inc.). The complexes were recovered from
Protein G magnetic beads, crosslinks were reversed and
DNA was purified. Four percent of both immunoprecipi-
tated and input chromatin were amplified by PCR using
Taq polymerase (Applied Biosystems by Roche Molecular
System, Inc) and the appropriate primers (ARE I (FOR):
50-TTCGAGAGTGAGGACGTGTG-30, ARE I (REV): 50-
AGGGAGCA GGAAA GTGAGGT-30, ARE II (FOR): 50-
TCACTGACTAACCCCGGAAC-30, ARE II (REV): 50-TT
TGG GACTGGAGTTGCTTC-30, ARE III (FOR): 50-
GGCTCTTTTAGGGGCTGAAG-30, ARE III (REV): 50-
AGGCTGATGAACGGGATATG-30, VEGF V88 (FOR) 50-
CCGCGGGCGCGTGTC TCTGG-30, VEGF V88 (REV)
50-TGCCCCAAGCCTCCGCGATCCTC-30). Following an
initial 10 min denaturation at 95°C, DNA was amplified
by 32–35 cycles of: 1) 20 sec denaturation at 95°C, 2) 30
sec annealing at either 52°C (for ARE III primers), 53°C
(for ARE II primers), 58°C (for ARE I and VEGF V88primers) and 3) 30 sec extension at 72°C; amplification
was completed with a 2 min final extension at 72°C. PCR
products were electrophoresed on 1% agarose gel, and
ethidium bromide stained DNA was visualized by a gel
doc system (Biorad, Hercules, CA).
For quantitation of immunoprecipitated chromatin by
quantitative real-time PCR (qRT-PCR), purified DNA
samples were amplified in an ABI 7000 thermocycler
using primers listed above and following manufacturer’s
recommendation for SYBR Green Q-PCR (Applied Bio-
systems, Foster City, CA). Each PCR reaction was carried
out in triplicate and average Ct values were normalized to
total input (non- immunoprecipitated) DNA. The amount
of DNA immunoprecipitated with the target antibody
from hormone treated cells R1881 was compared to that
of control samples treated only with vehicle. Shown are in-
put normalized Ct values from chromatin of treated cells
relative to untreated control cells.
RNA isolation and quantitative real-time PCR
RNA was isolated from subconfluent cells using the Gen-
Elute Mammalian Total RNA Miniprep Kit (Sigma, St.
Louis, MO) as per manufacturer’s recommendation. Fol-
lowing quantitation, 1μg of RNA was reverse transcribed
using the High Capacity cDNA ReverseTranscription Kit
(Applied Biosystems, Carlsbad, CA). qRT-PCR was per-
formed using either Taqman Universal Master Mix with
pre-designed Taqman Gene Expression Assay probe sets
for VEGFA (Hs00900057_m1) and 18S (Hs99999901_s1)
or SYBR Green Master Mix with primers specific for
VEGF, Sp1, GAPDH, and Beta-actin: VEGF (FOR): 50-CG
AAACCATGAACTTTCTGC-30, VEGF (REV): 50-CCT
CAGTGGGCACACACTCC-30, Sp1 (FOR) 50-TGCATTT
CAAGGAATGGAAT-30, Sp1 (REV) 50-GCTTCCTTGGT
GTGAAGAGA-30, GAPDH (FOR): 50-CCATCACCATC
TTCCAGGAG-30, GAPDH (REV): 50-GGATGATGTTCT
GGAGAGCC-30, Beta-actin (FOR): 50-GTGGGGCGCC
CCA GGCACCA-30, Beta-actin (REV): 50-GTCCTTAAT
GTCACGCACGATTTC-30). The comparative Ct method
[30] was used to analyze gene expression differences be-
tween control (untreated) cells and cells treated with
R1881 alone or with the anti-androgen casodex.
Western blot
Subconfluent monolayers of LNCaP and 22Rv1 cells
were washed in PBS and proteins were extracted using
RIPA lysis buffer (1% NP40, 0.5% Na Deoxycholate, 0.1%
SDS, and 150 mM NaCl) containing protease inhibitors.
To quantify the amount of proteins present in each
lysate, bicinchoninic acid (BCA) assays (Pierce, Thermo
Fisher Scientific, Rockford, IL) were performed and
absorbance was measured at 600nm on a Dynex Tech-
nologies (Chantilly, VA) MRX Revelation plate reader.
Proteins (25-50ug) were separated by sodium dodecyl
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After transfer to a Polyvinylidene Fluoride (PVDF) mem-
brane and blocking with 5% casein, blots were probed over-
night at 4°C with polyclonal VEGF and AR antibodies
(Santa Cruz), and monoclonal β-actin antibody (GenScript).
Washed blots were then incubated for 1 hr in either HRP-
conjugated anti – rabbit (GenScript) or anti – mouse
(Santa Cruz) antibodies. Proteins were visualized by incu-
bating the membrane in a luminol ECL solution followed
by chemiluminescent detection using a Fuji LAS 3000
(GE, Piscataway, NJ) detection system. Bands were quanti-
fied using ImageJ analysis and normalized to actin levels.
Co-Immunoprecipitation
Nuclear extracts from 22Rv1 cells were prepared using
Active Motif ’s Universal Magnetic Co-IP kit (Carlsbad,
CA) as per manufacturer’s recommendations. Cells were
swelled in Hypotonic Buffer containing phosphatase-,
deacetylase-, and protease- inhibitors, then lysed in 5%
detergent. This suspension was then centrifuged at
14,000 x g and the supernatant was discarded leaving
the nuclear fraction which was enzymatically sheared in
the presence of the same inhibitors. Nuclear extracts
(150-200μg) were then combined with 5μg of either AR
(Santa Cruz) or Sp1 (Upstate) antibodies, or negative
control IgG in the presence of the same inhibitors. Fol-
lowing antibody incubation, complexes were pulled
down with Protein G magnetic beads. After washing,
these complexes were separated by SDS-PAGE and iden-
tified by Western blot analysis (as described above).
Plasmid Transfection and Luciferase Assay
The pGL3-VEGF luciferase reporter constructs (V88, V411,
or V2274) were generously provided by Dr. Xie [16] and
DNA purified by the Qiagen plasmid Maxi prep kit
(Qiagen, Valencia, CA). LNCaP and 22Rv1 cells were plated
in 12-well plates as described above. After reaching ~70-
90% confluency, cells were serum-starved for 18–24 hours
with serum-free RPMI and then transfected with VEGF
reporter constructs using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) as described [7]. After 4–6 hours, transfec-
tion media was replaced with appropriate growth media.
For hormone induction, 5nM R1881 was added to media
with 5-10% charcoal-dextran stripped FBS as described
above. After 48 hours cells were lysed and luciferase activity
was measured using a Promega luciferase assay kit (Pro-
mega, Sunnyvale, CA) and aTurner luminometer (Promega,
Sunnyvale, CA) following manufacturer’s recommendations.
The luciferase activity was normalized to total cell protein,
using a micro BCA protein assay, as described above. All
experiments were done in triplicate and repeated at least
three times. Standard errors of the mean were determined
using GraphPad InStat software (San Diego, CA). Signifi-
cance was determined by Student’s t-test.Site directed mutagenesis
Potential binding sites in the VEGF promoter were identi-
fied using MatInspector, as previously described [11]. Pre-
dicted AR and Sp1 binding sites in the VEGF promoter
construct were then mutated using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene, Agilent Technolo-
gies, Santa Clara, CA). Primers were designed according
to the manufacturer’s suggestions using the QuikChange
Primer Design Program. Primers containing the desired
mutation (shown in bold) are listed below:
(ARE I (FOR):
50-CTCTATCGATAGGTACCGTGGTCAGCTCTCCC
C ACCCGTC CCTGTC-30,
ARE I (REV): 50GACAGGGACGGGTGGGGAGAGCT
GACCACGGTACCTATCGATAGAG-30,
ARE II (FOR): 50-GGAACCACACAGCTTCCCACTGT
CAGCTCCACA AAC TTGG-30,
ARE II (REV): 50-CCAAGTTTGTGGAGCTGACAGT
GGGAAGCTGTGTGGTTCC-30,
ARE III (FOR): 50-GCCCCAAGATGTCTACAGCTTA
CGGTCCTGGGGTGC-30,
ARE III (REV): 50-GCA CCCCAGGACCGTAAGCTG
TAGACATCTTGGGGC-30,
Sp1.2/Sp1.3 (FOR): 50-GCCCC CCG GTT CGGGCCG
GGTTCGGGGTCCC-30,
Sp1.2/Sp1.3 (REV): 50-GGGACCCCG AACC CGG
CCC GAA CCGGGGGGC-30,
Sp1.4 (FOR): 50-GGGTCCCGGCGGTTCGGAGCCAT
GCG-30,
Sp1.4 (REV): 50-CGCATGGCTCCGAACCGCCGGGA
CCC-30).
PCR was performed using the V88, the V411, or the
V2274 luciferase reporter constructs and the appropriate
mutant primers. After PCR amplification, parental
strands were digested with DpnI and XL1-Blue super
competent cells were transformed with remaining mu-
tant DNA. Individual colonies were grown, plasmids
were purified (Qiagen, Valencia, CA) and sequenced to
verify that the correct base pairs were changed (Cleve-
land Clinic Genomics Core, Lerner Research Institute,
Cleveland, OH). Luciferase assays were performed using
mutant constructs as described above.Additional files
Additional file 1: Figure S1. R1881 (1nM) induces VEGF mRNA
expression in LNCaP cells. LNCaP cells were serum starved overnight
followed by treatment with either 0nM R1881 (DMSO) or 1nM R1881 for
48 hours. VEGF mRNA expression was measured by qRT-PCR and
normalized to 18S levels as described. Values represent fold change
relative to DMSO treatment. A Student’s t-test was performed and
significance was determined ** (p < 0.01).
Additional file 2: Figure S2. Mutation of the Sp1.4 binding site does
not eliminate basal activity of the VEGF core promoter. 22Rv1 cells were
transfected with mSp1.4 (in V88 core promoter construct) or pGL3- Basic
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performed as described. Experiments were performed in triplicate and
repeated twice. Luciferase activity is shown relative to average
normalized activity of the pGL3-Basic empty vector. Significance was
determined by Student’s t-test *** (p < 0.001).
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